August 2012
-
According to Nexus6, a study conducted in New Zealand has shown that 84% of children using the Smartinhaler SmartTrack device, which provides both audio and visual reminders, used their inhalers as prescribed compared to 30%… Read more . . .
-
Inhalation Asia has announced that nicotine delivery, smoking cessation, and the treatment of tuberculosis will be among the topics addressed at IA15, to be held this September in Shenyang, China. Plenary speakers for the meeting… Read more . . .
-
NovaBiotics, which has plans to develop an inhaled version of its Lynovex cysteamine (NM001) for the treatment of cystic fibrosis, has announced that it has raised £5 million in a private placement from Woodford Investment… Read more . . .
-
Aradigm Corporation announced that it has received patents for its Pulmaquin inhaled ciprofloxacin from the European and Australian patent offices. The European patent (EU Patent No. 2,079,443) is titled “Dual Action, Inhaled Formulations Providing Both… Read more . . .
-
According to MannKind Corporation, Hakan Edstrom has taken over as CEO after company founder Alfred Mann stepped down from that position effective January 9, 2015. Mann will become the Executive Chairman and “intends to remain… Read more . . .
-
According to Verona Pharma a Phase 1/2 trial of its RPL554 inhaled PDE3/4 inhibitor for the treatment of COPD has gotten underway with dosing of the first subjects. Plans are for recruitment of up to… Read more . . .
-
Hovione has announced the promotion of Filipe Gaspar to VP of R&D, reporting to CEO Guy Villax. Gaspar joined Hovione in 2003 and has held a number of positions at the company, including Director of… Read more . . .
-
Researchers at Wake Forest Baptist Medical Center have announced results of a study in which 60 patients with amnesic mild cognitive impairment or mild to moderate Alzheimer’s dementia received one of two doses of an… Read more . . .
-
Egalet Corporation, which is developing several treatments for chronic pain, has announced the acquisition of Sprix ketorolac tromethamine nasal spray from Daiichi Sankyo subsidiary Luitpold Pharmaceuticals for $7 million. Ketorolac is a non-steroidal anti-inflammatory drug… Read more . . .
-
Pharmaceutical propellant market leader Mexichem has announced its acquisition of a distribution and sale license for DuPont’s pharmaceutical grade Dymel 227ea/P propellant and says that it will market the product under its Zephex brand. Zephex… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland